Navigation Links
FDA Approves Nulojix for Kidney Transplant Patients
Date:6/15/2011

SILVER SPRING, Md., June 15, 2011 /PRNewswire-USNewswire/ --The U.S. Food and Drug Administration today approved Nulojix (belatacept) to prevent acute rejection in adult patients who have had a kidney transplant. The drug is approved for use with other immunosuppressants (medications that suppress the immune system) -- specifically basiliximab, mycophenolate mofetil, and corticosteroids.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Nulojix is a type of drug called a selective T-cell costimulation blocker. The drug helps to prevent organ rejection after a kidney transplant. Without immunosuppression, the body can reject a transplanted organ because the immune system recognizes the new organ as foreign (transplant rejection). By preventing rejection, Nulojix, given through 30 minute intravenous infusions, works with other immunosuppressants to keep the new kidney working.

"Nulojix is a new option for kidney transplant patients," said Edward Cox, M.D., M.P.H., director, Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research. "This new medication used in combination with other immunosuppressants helps control the immune system and prevents organ rejection in patients receiving kidney transplants."

Nulojix was evaluated in two open-label, randomized, multicenter, controlled Phase 3 studies that enrolled more than 1,200 patients and compared two dose regimens of Nulojix with another immunosuppressant, cyclosporine. These trials demonstrated that the recommended Nulojix regimen is safe and effective for the prevention of acute organ rejection.

Nulojix carries a Boxed Warning for an increased risk of developing post-transplant lymphoproliferative disorder (PTLD), a type of cancer where white blood cells grow out of control after an organ transplant. The risk of PTLD is higher for transplant patients who have never been exposed
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves New Test To Help Determine if Breast Cancer Patients Are Candidates for Herceptin Treatment
2. FDA Approves First Ceramic-on-Metal Total Hip Replacement System
3. FDA Approves Redesigned Labels for Some Merck Drugs
4. FDA Approves Updates to Lillys Humalog® (insulin lispro injection [rDNA origin]) Label
5. FDA Approves Marketing of RMS Subcutaneous Needle Sets
6. FDA Approves Injectable Gel to Treat Fecal Incontinence
7. FDA approves Incivek for hepatitis C
8. FDA Approves Sutent for Rare Type of Pancreatic Cancer
9. FDA Approves New HIV Treatment
10. FDA Approves Victrelis for Hepatitis C
11. FDA Approves New Treatment for Rare Type of Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Animal Emergency Critical Care, a LifeCentre partner practice, located at ... is the first in Loudoun County to ... Susan M. Barnes , Medical Director, is a well-seasoned veterinarian ... Cole Taylor , are avid scuba divers. "As altitude skiers and ...
(Date:1/14/2014)... NineSigma , Inc., the leading innovation partner ... Summit , May 14-16, 2014 at the Global Center ... . This is the premier industry ... achievements through open innovation. Participants will learn how world-changing ...
(Date:1/14/2014)... WASHINGTON, New York , January 14, 2014 ... leading provider of Closed System Transfer Devices (CSTD) for hazardous drugs, today ... growth for the fourth straight year.   ... exposure for pharmacy technicians, pharmacists, nurses and other ...
Breaking Medicine Technology:Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Equashield's Sales Grow by 60% in 2013 2
(Date:4/18/2014)... 2014) ― A new study in the American ... health-related Google searches reveals a recurring pattern that could ... , Investigators from San Diego State University, the Santa ... analyzed "healthy" Google searches (searches that included the term ... in the U.S. from 2005 to 2012. They found ...
(Date:4/18/2014)... scientists could lead to potential new treatments for breaking ... , Fibrosis, or scarring, is a hallmark of ... lungs can lead to serious organ damage and, in ... options centers on findings made by Swati Bhattacharyya, PhD, ... that a specific protein plays in promoting fibrosis. ...
(Date:4/17/2014)... inflammation in non-cancerous prostate tissue may have nearly twice ... with no inflammation, according to results of a new ... Cancer Center. , The link between persistent inflammation and ... prostate cancer those with a Gleason score between ... most aggressive and rapidly growing prostate cancers. , "What ...
(Date:4/17/2014)... pain relief targets that could be used to ... King,s College London made the discovery when researching ... of the body. , Dr Marzia Malcangio said: ... pain generation and our findings could help chemotherapy ... One potential side effect of some chemotherapy drugs ...
(Date:4/17/2014)... today in PLOS Pathogens , children who live ... can mount an immune response to infection with malaria ... of high fever and illness and partially control the ... may help researchers develop future interventions that prevent or ... Each year, approximately 200 million cases of malaria occur ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:New clues on tissue scarring in scleroderma 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:New pain relief targets discovered 2Health News:Study sheds light on how the immune system protects children from malaria 2
... ... there are 6 key components of a successful strategic workforce planning process,” stated Jim ... components of strategic workforce planning and provides guidelines for implementing each of those 6 ... Waco, ...
... All Allied ... the health care industry. , ... (PRWEB) August 19, 2009 -- Today, All Allied Health Schools announced the launch of a new ... latest developments in the health care industry--and how these changes will affect health care careers ...
... Computed tomography (CT) scans are responsible for more than ... medical imaging exams. However, a newly adapted low-dose technique ... to reduce patient radiation resulting from CT up to ... September issue of the American Journal of Roentgenology ...
... led to fewer surgical deliveries, review shows , TUESDAY, ... increase the risk of Cesarean section delivery, according to ... Researchers reviewed available data on elective induction, in which ... it for medical reasons. Most of the studies included ...
... , , , ... Pharmaceutical Companies, Inc. (NYSE: PRX ) today announced ... final approval from the U.S. Food and Drug Administration for ... Clonidine TDS is a generic version of Boehringer Ingelheim,s ...
... , CHICAGO, Aug. 18 Synch-Solutions is ... on Inc. magazine,s 2009 list of the 5,000 fastest ... Synch-Solutions, reflecting the company,s strong and steady advancement - even in ... and technology solutions for organizations across multiple industry sectors. "As an ...
Cached Medicine News:Health News:Profiles International Releases New Study Identifying Key Factors for Strategic Workforce Planning 2Health News:All Allied Health Schools Launches "Health Care Community" 2Health News:All Allied Health Schools Launches "Health Care Community" 3Health News:Induced Labor May Prevent Need for Cesarean Section 2Health News:Par Pharmaceutical & Aveva Drug Delivery Systems Receive Final Approval to Market Generic Catapres TTS(R) 2Health News:Par Pharmaceutical & Aveva Drug Delivery Systems Receive Final Approval to Market Generic Catapres TTS(R) 3Health News:Synch-Solutions Named to Inc. Magazine's 2009 Ranking of the Fastest Growing Companies in the United States 2
Storage temperature: 15 - 30C, linearity: 0 - 20 mg/dL, expected value: male: 3.0 - 7.0 mg/dL and female: 2.2 - 6.2 mg/dL. Available with calibrator and number of tests 125....
For the quantitative determination of Uric Acid in serum. Linearity: 25 mg/dl....
... Engineered for small and medium volume ... Elecsys 1010 System offers the speed, simplicity ... testing requirements. Compact yet powerful, the Elecsys ... from rapid response assays to routine testing ...
Sample throughput of up to 80 tests per hour (4 modules). Low maintenance requirements. Continuous random access. 25 - 100 channels on board. 1008 tests or 6 hours of walkaway operation....
Medicine Products: